Wed, Jul 30, 2014, 11:39 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

SIGA Technologies, Inc. Message Board

  • tla_usa tla_usa Aug 7, 2013 8:58 PM Flag

    International sales -- biodefense -- Marketing Approval

    Excerpts via KVISTGAARD, Denmark, August 7, 2013 /PRNewswire/ --
    ----------------------------------------------------------------------------------------------
    =====Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has granted marketing authorization for IMVANEX® (MVA-BN) for active immunization against smallpox disease

    ======This is the first European approval of a novel biodefense vaccine developed through a successful public-private partnership with the U.S. government.

    ======IMVANEX is the only smallpox vaccine approved through the centralized European Union procedure

    ======IMVAMUNE/IMVANEX has also been supplied to other government stockpiles around the world.

    ====== Since 2010, Bavarian Nordic has been delivering the vaccine to the U.S. Strategic National Stockpile for emergency use in immune compromised individuals, such as people with atopic dermatitis and HIV who are not recommended to receive conventional, replicating smallpox vaccines.

 
SIGA
2.68-0.02(-0.74%)Jul 30 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.